Company* (Symbol) | Product | Description | Indication | Status (Date) |
CANCER |
||||
Allos Therapeutics Inc. (ALTH) | RSR13 | Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue | Recurrent malignant glioma | Phase Ib/II study of RSR13 administered with BCNU (carmustine) chemotherapy is under way (1/16) |
AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF) | OvaRex | Modified murine monoclonal antibody that binds to CA125 cancer antigen | Ovarian cancer | Phase II trial final results indicated the compound increases survival (1/3) |
Antisoma plc (UK; LSE:ASM; ASOM) | TheraFab | Injectable radiolabeled antibody fragment used in combination with external beam radiotherapy | Tumors | Company started the first clinical study (1/29) |
Atrix Laboratories Inc. (ATRX) | Leuprogel | Leuprolide acetate for subcutaneous depot injection | Advanced prostate cancer | Enrollment began for a Phase III trial (1/29) |
AVI BioPharma Inc. (AVII) | Avicine | Nontoxic therapeutic cancer vaccine, which elicits a highly specific immune response to human chorionic gonadotropin | Colorectal cancer | Company initiated a Phase III trial (1/4) |
British Biotech plc (UK; LSE:BBG; BBIOY) | Marimastat | Oral matrix metalloproteinase inhibitor | Small-cell lung cancer | Company completed a clinical trial of marimastat (1/19) |
Cell Genesys Inc. (CEGE) | GVAX | Cancer vaccine comprised of tumor cells that have been irradiated and genetically modified to secrete granulocyte macrophage-colony stimulating factor | Pancreatic cancer | Three of eight patients who received a higher dose of GVAX in combination with surgery remained disease-free and alive at 38, 35 and 33 months after diagnosis; results were published in the Journal of Clinical Oncology (1/2) |
Cell Therapeutics Inc. (CTIC) | Trisenox | Arsenic trioxide injection | Multiple myeloma | Company initiated the first of several company-sponsored multicenter clinical trials with Trisenox injection (1/31) |
Genta Inc. (GNTA) | Genasense | Antisense compound; synthetic DNA strands that bind to mRNA for the bc12 gene | Acute myeloid leukemia and chronic lymphocytic leukemia | Company initiated two clinical trials in relapsed patients (1/19) |
Immuno-Designed Molecules SA* (France) | IDD-3 | Cellular vaccine composed of dendritophages loaded in vitro with specific tumor antigens derived from cancer cell extracts, called lysates | Malignant melanoma | Company launched a Phase II trial (1/29) |
Inex Pharmaceuticals Corp. (Canada; INEX) | Onco TCS | Therapeutic consisting of vincristine encapsulated in Inex's transmembrane carrier systems drug delivery technology | Non-Hodgkin's lymphoma | Company began screening patients for its pivotal Phase II/III trial evaluating Onco TCS (1/31) |
IntraBiotics Pharmaceuticals Inc. (IBPI) | Protegrin IB-367 | A rinse; synthetically derived analogue of naturally occurring protegrins | Cancer | Company completed patient enrollment in its Phase III trial (1/16) |
Ligand Pharmaceuticals Inc. (LGND) | Ontak | Denileukin difitox; fusion protein consisting of fragment of diphtheria toxin genetically fused to interleukin-2 | Persistant or refractory cutaneous T-cell lymphoma | Results showing Ontak induces partial and complete responses in patients were published in the Journal of Clinical Oncology (1/22) |
NeoRx Corp. (NERX) | Pretarget technology | Designed to deliver therapeutic products to tumor sites | Non-Hodgkin's lymphoma | Company began a Phase I trial (1/10) |
Peregrine Pharmaceuticals Inc. (PPHM) | Cotara | Tumor necrosis therapy; chimeric monoclonal anti-body that targets DNA-associated histone antigens, labeled with I-131 | Recurrent or unresectable malignant glioma | Phase II trial indicated median time to progression of about 14 weeks, a 75% increase over historical data for the 16 evaluable patients (1/9) |
Pharmacyclics Inc. (PCYC) | Xcytrin | Motexafin gadolinium injection | Brain metastases | Phase III trial reached 90% enrollment and the compound was found to be safe (1/9) |
Progenics Pharmaceuticals Inc. (PGNX) | MGV | Cancer vaccine designed to stimulate a patient's immune system to control or eradicate residual cancer cells after surgery, radiation or chemotherapy | Cancer | Trial results published in Clinical Cancer Research showed the vaccine to be free of significant toxicity and that it induced antibodies against two different targets on cancer cells (1/24) |
SciClone Pharmaceuticals Inc. (SCLN) | Zadaxin | Immune system enhancer used in combination with radio frequency abalation | Hepatocellular carcinoma | Company initiated a Phase II study (1/8) |
CARDIOVASCULAR |
||||
Alexion Pharmaceuticals Inc. (ALXN) | Pexelizumab (formerly 5G1.1-SC) | An anti-inflammatory C5 inhibitor monoclonal antibody fragment | For patients undergoing cardiac surgery with cardiopulmonary bypass | Phase IIb results showed pexelizumab suppressed complement in CPB patients and appears to be safe and well tolerated; pexelizumab also reduced the composite incidence of death or myocardial infarction by 41% at 30 days (1/23) |
Alliance Pharmaceutical Corp. (ALLP) | Oxygent | Perflubron emulsion; intravascular oxygen carrier or blood substitute that carries oxygen to tissues through the bloodstream | Patients undergoing cardiac bypass | Company stopped enrollment in Phase III due to an imbalance in adverse events, particularly the incidence of stroke (1/9) |
Avant Immunotherapeutics Inc. (AVAN) | TP10 | Soluble form of complement receptor 1, designed to inhibit complement proteins | For infants undergoing high-risk cardiac surgery using cardiopulmonary bypass | Company began a Phase IIb trial (1/4) |
Chiron Corp. (CHIR) | FGF-2 | Recombinant fibroblast growth factor-2 protein | Peripheral artery disease | Phase II results presented at the American Heart Association Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization indicated the primary efficacy endpoint, peak walking time at day 90, showed positive trends, but did not reach statistical significance (1/27) |
CV Therapeutics Inc. (CVTX) | Ranolazine | Part of pFOX (partial | Stable angina fatty acid oxidation) | Company plans to enroll an additional 186 patients in a 462-patient Phase III study (1/5) |
IDEC Pharmaceuticals Inc. (IDPH) | IDEC-131 | Humanized anti-CD154 monoclonal antibody | Chronic, refractory immune thrombocytopenic purpura | Company initiated a Phase II trial (1/4) |
Neuron Therapeutics Inc.* | Revoxyn | Oxygenated fluorocarbon nutrient emulsion | Severe ischemic stroke | Company initiated a Phase I trial (1/29) |
CENTRAL NERVOUS SYSTEM |
||||
Alexion Pharmaceuticals Inc. (ALXN) | 5G1.1 | Anti-inflammatory C5 inhibitor monoclonal antibody | Rheumatoid arthritis | Phase II interim results showed the study met its primary end-point (1/29) |
AlphaRx Inc. (Canada; OTC BB: AHRX) | Indoflex | Indomethacin; nonsteroidal anti-inflammatory drug | Pain | Company initiated a trial to assess the drug's pharmacokinetics, rate of onset, gastrointestinal irritation properties and patient tolerance (1/3) |
Biogen Inc. (BGEN) | Avonex (FDA-approved) | Interferon beta-1a | Secondary progressive multiple sclerosis | Company's IMPACT study achieved its primary endpoint, reducing the progression of disability by 27% vs. placebo (1/16) |
NicOx SA (France; Nouveau Marche:NICOX) and AstraZeneca plc (UK) | HCT-3012 | NO-NSAID compound | Pain and inflammation | Companies initiated Phase II trials (1/24) |
Scios Inc. (SCIO) | SCIO-469 | Novel oral p38 kinase inhibitor | Rheumatoid arthritis | Phase I data indicated the drug is well tolerated in healthy volunteers (1/24) |
SkyePharma plc (UK; LSE:SKP; SKYE) | DepoMorphine | Sustained-release morphine formulation using Skye-Pharma's DepoFoam injection technology | Moderate to acute post-operative pain | Company started Phase III trials involving 750 patients in the U.S. and Europe (1/10) |
Titan Pharmaceuticals Inc. (AMEX:TTP) | Spheramine | Cell therapy product that uses human retinal pigmented epithelial cells that secrete dopamine | Parkinson's disease | Company began treatment in the first cohort of patients receiving Spheramine in a Phase I/II study (1/25) |
Vertex Pharmaceuticals Inc. (VRTX) | VX-745 | Small-molecule inhibitor of p38 MAP kinase, which regulates the production of tumor necrosis factor-alpha and interleukin-1 | Rheumatoid arthritis | Company began a Phase II trial (1/4) |
DIABETES |
||||
Insmed Inc. (INSM) | INS-1 | Oral insulin sensitizer used in combination with sulfonylurea | Type II diabetes | Full analysis of a Phase II trial showed patients experienced statistically significant improvement in glycohemoglobin compared to those receiving sulfonylurea alone (1/5) |
INFECTION |
||||
Antex Biologics Inc. (AMEX:ANX) | Campyvax | Campylobacter infection vaccine | Campylobacter infection | Phase II results indicated the compound produces significant immune responses that correlate with protection against disease (1/9) |
Corixa Corp. (CRXA) | RC-529 | Synthetic adjuvant used in combination with AgB vaccine | Hepatitis B virus | Company initiated a Phase III trial (1/11) |
CV Technologies Inc. (Canada; CDNX:CVQ) | CVT-E002 | A multicomponent phytopharmaceutical | Cold and flu | Company started a second Phase II trial (1/18) |
Enzo Biochem Inc. (NYSE:ENZ) | HGTV43 | HIV-1 gene medicine product | HIV | Company said it achieved successful results in its Phase I trial and is planning to extend the study (1/11) |
MediGene AG* (Germany) | Polyphenon E | Antioxidative, anti-inflammatory and blocks virus binding to the cell; has antitumor activity | Genital warts caused by human papillomavirus | Company initiated a Phase III trial (1/4) |
SciClone Pharmaceuticals Inc. (SCLN) | Zadaxin | Subcutaneous injectable immune system enhancer | Hepatitis C | Company initiated a pivotal Phase III trial in the U.S. (1/10) |
Stressgen Biotechnologies Corp. (Canada; TSE:SSB) | HspE7 | Recombinant fusion product composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7, derived from the human papillomavirus dysplasia | Genital warts caused by human papillomavirus | Company initiated a Phase II trial (1/9) |
|
Trimeris Inc. (TRMS) and F. Hoffmann-La Roche Ltd.(Switzerland) | T-20 and T-1249 | Members of a new class of anti-HIV drugs called fusion inhibitors | HIV | Early study results indicate the drugs could offer patients resistant to other products an option in slowing the progression of the disease (1/29) |
MISCELLANEOUS |
||||
Adolor Corp. (ADLR) | ADL 8-2698 | Orally administered, gutselective narcotic antagonist | Opioid bowel dysfunction | Phase II results showed the compound mitigates the severe opioid-induced bowel dysfunction in patients taking narcotics without interfering with the narcotics' analgesic effects (1/18) |
AeroGen Inc. (AEGN) | AeroDose | Albuteral inhaler | Asthma | Company entered Phase II trials (1/9) |
Alteon Inc. (AMEX:ALT) | ALT-711 | Advanced glycosylation endproduct crosslink breaker | Advanced glycosylation endproduct crosslink formation | Phase IIa trial results indicated patients experienced a statistically significant reduction in arterial pulse pressure and a clinically relevant increase in larger artery compliance (1/3) |
Amarillo Biosciences Inc. (OTC BB:AMAR) | | Oral interferon-alpha | Sjogren's syndrome | Company completed its second Phase III trial, which noted an increase in saliva production and improvements in oral symptoms (1/5) |
Atrix Laboratories Inc. (ATRX) | Atrisone | Dapsone topical gel in SMP technology | Acne | Company plans to begin the first of its Phase III studies (1/3) |
Avant Immunotherapeutics Inc. (AVAN) | CETi-1 | Therapeutic vaccine against endogenous cholesterylester transfer protein (CETP), a key intermediary in the distribution of cholesterol between high-density lipoprotein and low-density lipoprotein | To treat patients with low levels of HDL cholesterol | Phase I trial indicated the compound is well tolerated (1/9) |
Biogen Inc. (BGEN) | Antegren | Humanized monoclonal antibody directed against the alpha-4-beta-1 integrin expressed in certain white blood cells | Multiple sclerosis and Crohn's disease | Phase II results showed Antegren achieved its endpoint of reduction of new gadolinium-enhancing lesions in multiple sclerosis; Antegren also reached its end-points of induction of remission in Crohn's disease (1/23) |
BioMarin Pharmaceutical Inc. (BMRN) and Genzyme General (GENZ) | Aldurazyme | Enzyme replacement therapy; recombinant alpha-L-iduronidase | Mucopolysacch-aridosis I (MPS-1) | Clinical trial results reported in the New England Journal of Medicine show the therapeutic has potential to alleviate the primary symptoms of MPS-1; data also indicate the therapy is well tolerated and effective (1/18) |
Cerus Corp. (CERS) and Baxter Healthcare Corp. (NYSE:BAX) | Intercept Platelet System | A system to inactivate bacteria, viruses and other pathogens and white blood cells in platelets intended for transfusion | To inactivate viruses, bacteria and other pathogens | Companies completed enrollment in the 600-patient Phase III trial (1/25) |
Endovasc Ltd. (OTC BB:ENDV) | Liprostin | Developed using liposome drug delivery technology to encapsulate prostaglandin E-1, a potent vasodilator, platelet inhibitor and anti-thrombotic | Critical limb ischemia | Company completed Phase I trials that showed the drug to be well tolerated and safe (1/16) |
Esperion Therapeutics Inc. (ESPR) | LUV | Large unilamellar vesicles; spherical particles comprised of naturally occurring lipids that recirculate through arteries | Atherosclerosis and low HDL-C | Company initiated a Phase IIa program (1/9) |
Genmab A/S (Denmark; CSE:GEN) | HuMax-CD4 | Fully human antibody | Severe psoriasis | Company initiated a Phase II trial (1/9) |
IDEC Pharmaceuticals Inc. (IDPH) | IDEC-114 | A primatized anti-CD80 monoclonal antibody | Moderate to severe psoriasis | Company initiated a Phase II trial (1/11) |
IDEC Pharmaceuticals Inc. (IDPH) | IDEC-131 | Humanized anti-CD154 moncolonal antibody | Psoriasis | Company initiated a Phase II trial (1/29) |
Incara Pharmaceuticals Corp. (INCR) | OP2000 | Subcutaneously administered ultra-low molecular weight heparin | Ulcerative colitis | Patients are now being enrolled and treated in a pivotal Phase II/III study of OP2000 (1/29) |
Inspire Pharmaceuticals Inc. (ISPH) | INS365 | P2Y(2) receptor agonist | Dry eye syndrome | Company initiated Phase III trials (1/9) |
Interneuron Pharmaceuticals Inc. (IPIC) and Pfizer Inc. (NYSE:PFE) | Pagoclone | Compound that potentiates action of the neurotransmitter gamma amino butyric acid (partial agonist) | Anxiety disorder | Companies initiated Phase II testing (1/16) |
Labopharm Inc. (Canada; TSE:DDS) | Xopenex | Leval buterol HCL | Asthma | Phase II results demonstrated significant improvement in breathing compared to placebo (1/9 |
Orthologic Corp. (OLGC) | Chrysalin | Synthetically manufactured peptide | Fracture healing | Company completed enrollment in its Phase I/II trial (1/18) |
Protein Design Labs Inc. (PDLI) | SMART Anti-Gamma Interferon | Antibody | Crohn's disease | Company began a Phase I/II trial (1/10) |
Vivus Inc. (VVUS) | Alista | Formulation of alprostadil, a naturally occurring vasodilating agent | Female sexual dysfunction | Company initiated enrollment in its Phase II study (1/23) |
